论文部分内容阅读
目的:探讨TP方案和NP方案诱导化疗联合放疗治疗Ⅲ期非小细胞肺癌的临床疗效和不良反应。方法:回顾分析我院2010年2月至2012年2月收治的76例Ⅲ期非小细胞肺癌患者,根据化疗方案的不同将76例患者分为TP组和NP组,两组患者均接受2周期的诱导化疗,化疗后进行常规分割放射治疗,总剂量为60-64Gy/30-32次,对比分析两种方案的近期疗效和不良反应情况,通过随访调查统计1、2年的生存情况。结果:TP组的近期有效率(CR+PR)为55.3%,NP组为47.4%。组间差异不明显无统计学意义(P>0.05);两组间贫血、食管炎、血小板减少等情况比较均无显著差异,无统计学意义(P>0.05)。静脉炎和白细胞减少情况差异具有统计学意义(P>0.05);两组患者的1年生存率分别为54.2%和50.3%;2年生存率为16.4%和15.1%。两组患者平均生存时间为14.3个月和13.5个月。TP组和NP组的远程疗效无显著差异,不具有统计学意义(P>0.05)。结论:TP方案和NP方案诱导化疗联合放疗治疗Ⅲ期非小细胞肺癌的临床疗效显著,有良好的耐受性和安全性,是两种合理、安全、有效、值得在临床上推广使用的治疗方案。
Objective: To investigate the clinical efficacy and adverse reactions of TP and NP regimen induction chemotherapy combined with radiotherapy in the treatment of stage Ⅲ non-small cell lung cancer. Methods: A retrospective analysis of 76 patients with stage Ⅲ non-small cell lung cancer admitted to our hospital from February 2010 to February 2012, 76 patients were divided into TP group and NP group according to the different chemotherapy regimens, two groups of patients received 2 Cycle of induction chemotherapy, conventional radiotherapy after chemotherapy, the total dose of 60-64Gy / 30-32 times, comparative analysis of the two programs of short-term efficacy and adverse reactions, follow-up survey statistics of 1, 2-year survival. Results: The effective rate (CR + PR) of TP group was 55.3% and that of NP group was 47.4%. There was no significant difference between the two groups (P> 0.05). There was no significant difference in anemia, esophagitis, thrombocytopenia among the two groups (P> 0.05). The difference of phlebitis and leukopenia was statistically significant (P> 0.05). The 1-year survival rates of the two groups were 54.2% and 50.3% respectively, and the 2-year survival rates were 16.4% and 15.1%. The average survival time of both groups was 14.3 months and 13.5 months. TP group and NP group no significant difference in long-term efficacy, not statistically significant (P> 0.05). Conclusion: TP and NP induction chemotherapy combined with radiotherapy in the treatment of stage Ⅲ non-small cell lung cancer have significant clinical efficacy, good tolerability and safety, and are two reasonable, safe and effective treatments that are worth popularizing in clinic Program.